Skip to main content
. Author manuscript; available in PMC: 2012 Dec 7.
Published in final edited form as: N Engl J Med. 2011 Jun 2;364(22):2119–2127. doi: 10.1056/NEJMoa1012863

Figure 1. Progression-free and Overall Survival.

Figure 1

Progression-free survival (Panel A) was longer among patients receiving vaccine and interleukin-2 than among those receiving interleukin-2 alone. The median progression-free survival among patients who received the vaccine was 2.2 months (95% confidence interval [CI], 1.7 to 3.9), as compared with 1.6 months (95% CI, 1.5 to 1.8) among patients who did not receive the vaccine. There was a trend toward longer overall survival (Panel B) among patients receiving vaccine and interleukin-2 than among those receiving interleukin-2 alone. The median survival among patients who received the vaccine was 17.8 months (95% CI, 11.9 to 25.8), as compared with 11.1 months (95% CI, 8.7 to 16.3) among patients who did not receive the vaccine.